rethinkPeptides Search
Menu
Study breakdown

Fish-Derived Collagen Peptide Promotes Hair Growth by Activating a Key Hair Follicle Pathway

evidence
The takeaway

A low molecular weight collagen peptide from fish promoted hair growth across human cell cultures, human hair follicles, and mice by activating the Wnt/β-catenin pathway — a master regulator of hair follicle formation and cycling.

Oral collagen peptide significantly stimulated hair growth in mice

LMWCP activated the Wnt/β-catenin pathway — a master regulator of hair follicle biology — increasing growth factors, new follicle formation, and hair-specific keratin expression

What the researchers found

Low molecular weight collagen peptide (LMWCP) from fish promoted hair growth across multiple experimental models: it stimulated human dermal papilla cell proliferation and mitochondrial activity, increased secretion of growth factors (EGF, HB-EGF, FGF-4, FGF-6), boosted new hair follicle formation in a dose-dependent manner in patch assays, promoted human hair follicle growth ex vivo, and significantly stimulated hair growth when given orally to mice. The mechanism involved activation of the Wnt/GSK-3β/β-catenin signaling pathway, with upregulation of Wnt3a, β-catenin, VEGF, PCNA, Cyclin D1, and hair-specific keratins.

Why it matters

Hair loss affects hundreds of millions of people worldwide, yet treatment options are limited (mainly minoxidil and finasteride). Collagen peptides are widely available as supplements and generally well-tolerated. If these preclinical results translate to humans, oral collagen peptide supplements could provide a new, accessible approach to promoting hair growth through a well-characterized molecular pathway (Wnt/β-catenin) that is central to hair follicle biology.

The numbers in context

Dose-dependent hair follicle neogeneration · Increased EGF, HB-EGF, FGF-4, FGF-6 · Upregulated Wnt3a, β-catenin, VEGF, PCNA, Cyclin D1 · Enhanced keratin Type I & II expression · Oral administration effective in mice

How the study worked

Multi-model study: (1) In vitro testing on human dermal papilla cells (hDPCs) measuring proliferation, mitochondrial activity, and growth factor secretion; (2) Patch assay for hair follicle neogeneration; (3) Ex vivo human hair follicle growth assessment; (4) In vivo oral administration to telogenic C57BL/6 mice with histological and molecular analysis of back skin. Wnt/β-catenin pathway activation was confirmed through protein expression and nuclear translocation studies.

Who was studied

Preclinical study using human dermal papilla cells, human hair follicles, and C57BL/6 mice

What this study cannot tell us

While multiple models were used, the study is preclinical — no human clinical trial of oral LMWCP for hair growth was conducted. The mouse model (telogenic C57BL/6) tests hair cycle re-entry rather than reversal of actual hair loss conditions like androgenetic alopecia. The fish-derived collagen peptide composition may vary between sources and batches. Oral bioavailability of the specific active peptide fractions is not fully characterized.

How to read the evidence

This is a comprehensive preclinical study using four complementary models (human cells, patch assay, human follicles, mice), which provides strong mechanistic evidence. However, no human clinical trial was conducted, and the resting-phase mouse model does not perfectly represent human hair loss conditions.

When this study was published

Published in 2024, this is recent research that builds on growing interest in collagen peptides as functional supplements and the Wnt/β-catenin pathway as a hair growth target.

The bigger picture

The Wnt/β-catenin pathway is recognized as one of the most important regulators of hair follicle biology — when active, it drives hair growth; when suppressed, hair enters the resting phase. Finding that an orally administered collagen peptide can activate this pathway is significant because most Wnt-targeting approaches in hair loss research require topical application or genetic manipulation. Collagen peptide supplements are already popular for skin and joint health, and this research could expand their applications to hair growth.

Questions still open

  • Would oral collagen peptide supplementation produce visible hair growth improvements in a human clinical trial?
  • Which specific peptide sequences within the LMWCP hydrolysate are responsible for activating the Wnt/β-catenin pathway?
  • Would LMWCP be effective for androgenetic alopecia (pattern baldness), which involves different mechanisms than the resting-phase mouse model used here?

Common questions

What is the Wnt/β-catenin pathway and why does it matter for hair?
The Wnt/β-catenin pathway is a cell signaling system that acts like a master switch for hair follicle development and cycling. When active, it tells hair follicle stem cells to grow and produce new hair. When it's turned off, hair enters a resting phase and eventually falls out. Many forms of hair loss involve reduced Wnt/β-catenin activity, making it one of the most important targets for hair growth research.
Should I take collagen peptide supplements for hair growth based on this study?
This study shows promising preclinical results, but it was done in cells and mice — not in people. While collagen peptides are generally safe and widely available, there's no guarantee the same hair growth effects would occur in humans. The specific type of collagen peptide (LMWCP from fish) and its processing may also differ from what's available commercially. Human clinical trials are needed before making strong recommendations.

Read the original research

Low Molecular Weight Collagen Peptide (LMWCP) Promotes Hair Growth by Activating the Wnt/GSK-3β/β-Catenin Signaling Pathway.

Journal of microbiology and biotechnology, 34(1), 17-28

Citation

Kim, Yujin; Lee, Jung Ok; Lee, Jung Min; Lee, Mun-Hoe; Kim, Hyeong-Min; Chung, Hee-Chul; Kim, Do-Un; Lee, Jin-Hee; Kim, Beom Joon. (2024). Low Molecular Weight Collagen Peptide (LMWCP) Promotes Hair Growth by Activating the Wnt/GSK-3β/β-Catenin Signaling Pathway.. Journal of microbiology and biotechnology, 34(1), 17-28. https://doi.org/10.4014/jmb.2308.08013